Skin Manifestations
Skin Manifestations
Explore linked clinical trials. Standard reference: MESH:M0019938280 results · Page 1 of 12
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | Cytopenia, Evans syndrome, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-10-09 | NCT07421167 | |
| A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06721013 | |
| TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years | Erythema, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin Manifestations, Skin and Connective Tissue Diseases, complement component 5 deficiency, dermatitis, sebaceous gland disorder, seborrheic dermatitis, skin disorder | Not yet recruiting | Not applicable | 2026-10-06 | NCT07860788 | |
| J-LINX: Japan LINerixibat eXtension Study | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis, skin disorder | Not yet recruiting | Phase 3 | 2026-10-06 | NCT07860710 | |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Cholangitis, Sclerosing, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Abnormalities, Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary atresia, biliary tract disorder, cholangitis, skin disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06553768 | |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | Edema, Erythema, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, breast carcinoma, breast disorder, breast neoplasm, inflammatory breast carcinoma, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-10-06 | NCT02876107 | |
| RTX001 Autologous Engineered Macrophages for Liver Cirrhosis | Brain Diseases, Metabolic, Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Jaundice, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, brain disorder, central nervous system disorder, chronic liver failure, cirrhosis of liver, hepatic encephalopathy, hyperbilirubinemia, liver disorder, liver failure, metabolic disease, nervous system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT06823713 | |
| Novel Strategies for Reducing Burn Scar Itch | Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, burn, injury, skin disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06801626 | |
| A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Recruiting | Not stated | 2026-10-02 | NCT07353099 | |
| A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Not stated | 2026-10-01 | NCT07786077 | |
| Comparative Autoantibody and Immunologic Cell Marker Study | AIDS, Blood-Borne Infections, Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Epstein-Barr virus infection, Flaviviridae infectious disease, Genital Diseases, Guillain-Barre syndrome, HIV infectious disease, Hemic and Lymphatic Diseases, Hemorrhage, Herpesviridae infectious disease, Immunoglobulin G4-Related Disease, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, Purpura, Thrombocytopenic, Idiopathic, RNA Virus Infections, Sepsis, Signs and Symptoms, Sjogren syndrome, Skin Manifestations, Skin and Connective Tissue Diseases, Slow Virus Diseases, Stomatognathic Diseases, Systemic Inflammatory Response Syndrome, Tumor Virus Infections, Undifferentiated Connective Tissue Diseases, Urogenital Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, autoimmune disorder of the nervous system, autoimmune lymphoproliferative syndrome, blood coagulation disease, blood platelet disease, connective tissue disorder, demyelinating disease, diffuse scleroderma, dry eye syndrome, eye disorder, graft versus host disease, hematologic disorder, hemorrhagic disease, hepatitis, hepatitis C virus infection, hereditary disease, immune system disorder, immunoproliferative disorder, inborn error of immunity, infectious disease, juvenile idiopathic arthritis, lacrimal apparatus disorder, lentivirus infection, liver disorder, lymphatic system disorder, lymphoproliferative syndrome, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy, purpura, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, sexually transmitted disease, skin disorder, systemic lupus erythematosus, systemic sclerosis, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy, uterine carcinosarcoma, viral hepatitis, viral infectious disease, viral sexually transmitted disease | Enrolling by invitation | Not stated | 2026-10-01 | NCT02422875 | |
| TGD001 Treatment in Thrombotic Microangiopathies | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT07459114 | |
| Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis | Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, nervous system disorder, neuralgia, neuromuscular disease, peripheral nervous system disorder, skin disorder | Recruiting | Not stated | 2026-09-28 | NCT07844772 | |
| Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation | Digestive System Diseases, Hypoxia, Jaundice, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Respiratory, Skin Manifestations, biliary tract disorder, cholelithiasis, hyperbilirubinemia, obstructive jaundice, pancreas disorder, pancreatitis | Not yet recruiting | Not applicable | 2026-09-25 | NCT07637721 | |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, autoimmune thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 / Phase 3 | 2026-09-24 | NCT07194850 | |
| A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05885555 | |
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias | Cytopenia, Disease Attributes, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Recurrence, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Phase 1 | 2026-09-23 | NCT07765966 | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 3 | 2026-09-23 | NCT04812925 | |
| Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin | Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, skin disorder | Not yet recruiting | Phase 2 | 2026-09-22 | NCT07833306 | |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, autoimmune hemolytic anemia, warm type, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07549698 | |
| Topical Minocycline for CARP | Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, cyclopia sequence, papillomatosis, confluent and reticulated, skin disorder | Not yet recruiting | Early phase 1 | 2026-09-21 | NCT07462702 | |
| A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-18 | NCT06722235 | |
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-17 | NCT07700238 | |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-14 | NCT07104565 | |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-14 | NCT07095127 |